(Fighting New Coronary Pneumonia) China introduces real-world data of domestically-made inactivated new coronavirus vaccines: it can significantly prevent severe illness and death
China News Service, Beijing, August 27 (Reporter Li Chun) Zheng Zhongwei, the leader of the vaccine research and development team of the Joint Defense and Joint Control Mechanism Research Team of the State Council of China, and the director of the Medical Science and Technology Development Research Center of the National Health Commission, introduced in Beijing on the 27th The real-world data of the domestically-made inactivated vaccine for the new crown, and pointed out that the vaccine can effectively prevent infection and significantly prevent severe illness and death.
On the same day, the Joint Prevention and Control Mechanism of the State Council of China held a press conference to further improve the situation of epidemic prevention and control and vaccination.
Zheng Zhongwei said that the vaccines currently provided by China to foreign countries are mainly two inactivated vaccines approved by the World Health Organization. One is from Sinopharm and the other is from Beijing Kexing.
Since May, Peru, Thailand, Chile, Argentina, Mongolia, Bahrain, Uruguay, Sri Lanka and other countries that have been vaccinated with China's new crown inactivated vaccine have successively released real-world research data.
"What needs to be clear is that due to the different prevention and control strategies of various countries, the prevalence of variant strains is also different, and the data released for the prevention of infection, severe illness and death by inactivated vaccines are also different." Zheng Zhongwei said, in general. The protection rate against infection ranges from 57% to 85%, the protection rate against severe illness is around 90%, and the protection rate against death is between 84% and 97%.
"Vaccines are not 100% preventing infections, nor are they 100% preventing severe illnesses and preventing deaths, but it can indeed effectively prevent infections and can significantly prevent severe illnesses and deaths."
According to Zheng Zhongwei, the Chilean Ministry of Health used more than 10 million people as a research sample and published the real-world research results of Coxing Zhongwei inactivated vaccines in the New England Journal of Medicine.
The results showed that the protection rate of the vaccine against infection was 65.9%, the protection rate against hospitalization was 87.5%, the protection rate against severe illness was 90.3%, and the protection rate against death was 86.3%. The Argentine Ministry of Health had two doses of Chinese biological inactivation. The death protection rate of people over 60 years of age with the vaccine was studied by age. The results showed that the overall protection rate was 84%, of which 80.2% was 60 to 69 years old, 88.3% was 70 to 79 years old, and 77.6% was over 80 years old. ; Sri Lanka also officially released a research report on the inactivated vaccine of Sinopharm Group. The report shows that the vaccine still has a good protective effect on the Delta strain.
In addition, the Sinopharm vaccine can also induce the immune response of T cells and memory B cells.
Zheng Zhongwei responded that it is neither necessary nor feasible for people who are more concerned about whether to conduct antibody testing on people who have been vaccinated. He explained that there are three reasons: first, the results of clinical trials have shown that the new coronavirus vaccine has strong immunogenicity; second, the level of antibodies gradually declines after vaccination, which is a natural response of the human immune system, but the level of antibodies has decreased , It does not mean that the vaccine loses its protective effect; thirdly, in history, the normal vaccine did not carry out the antibody test of the population, and there is no legal requirement in this regard, so there is no need to carry it out. (over)